Evidence supports the central role of lifestyle interventions, including nutritional strategies and physical activity in reducing cardiometabolic risk
According to the SmPC, nausea is very common, affecting a significant proportion of patients, particularly during dose escalation
Dyspareunia may occur due to dryness of the external genitalia
Do GLP-1 medications lower heart risk in rheumatoid arthritis
Tirzepatide During Illness Tirzepatide also has a weekly dosing schedule with a similar half-life, but its dual mechanism (GLP-1 and GIP receptor agonist) creates slightly different considerations: Appetite Effects : Some patients report stronger appetite suppression with tirzepatide compared to semaglutide
Patients considering GLP-1 receptor agonist or dual GIP/GLP-1 therapy should understand that these medications facilitate weight loss through appetite reduction and decreased food intake, not by "speeding up metabolism" or burning additional calories at rest
